Compared with ROPRO, this model specifically focused on patients with aNSCLC receiving anti‐PD‐1/PD‐L1 CPIs as 2L monotherapy vs a more general, pooled cohort of 17 different tumor types who had received 1L treatment.9 The gene discussed is PDCD1; the disease is neoplasm.